0897.HK

Drug and healthcare products maker Wai Yuen Tong Medicine Holdings Ltd. (0897.HK) announced on Wednesday its revenue fell 5.8% year-on-year to HK$347 million ($45 million) in the six months to September. But its profit of HK$23.7 million was up 577% over the same period.

The big profit gain, even as revenue fell, owed mainly to fair value gains related to the company’s investment properties. At the same time, its net impairment losses on properties, plants and equipment were smaller than the same period last year.

Wai Yuen Tong said its sales for the six-month period fell by 7.3% year-on-year due to changes in consumption patterns among local residents and tourists. To counter such negative effects, the company launched new products under the Wai Yuen Tong brand, expanded cross-border e-commerce channels, and cooperated with celebrities and key opinion leaders to increase its visibility.

Wai Yuen Tong’s shares fell 0.4% in Thursday trade in Hong Kong.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click  here

Recent Articles

Geneplus IPO

Geneplus locks onto targeted medicine for IPO pitch

After a post-Covid earnings dip, the company is seeking a stable future as a provider of data and diagnostics for precision medicine and disease prevention   Key Takeaways: The company’s…

Hong Kong’s IPO rally under scrutiny, as ZTE hits new U.S. headwinds

Hong Kong's stock regulator has warned IPO underwriters over the declining qualiy of new listing applications. Is this a red flag for the city's booming IPO market, or just the usual regulatory caution? And the U.S. could fine telecoms equipment maker ZTE $1 billion for bribery in Brazil. Why does Washington think it can force ZTE to pay such a large amount?